1713 related articles for article (PubMed ID: 26045659)
1. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
2. PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway.
Bao W; Liu R; Wang Y; Wang F; Xia G; Zhang H; Li X; Yin H; Chen B
Int J Nanomedicine; 2015; 10():557-66. PubMed ID: 25609961
[TBL] [Abstract][Full Text] [Related]
3. Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system.
Guo L; Zhang H; Wang F; Liu P; Wang Y; Xia G; Liu R; Li X; Yin H; Jiang H; Chen B
Int J Nanomedicine; 2015; 10():4535-47. PubMed ID: 26213467
[TBL] [Abstract][Full Text] [Related]
4. Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation.
Bao W; Liu R; Xia G; Wang F; Chen B
Drug Des Devel Ther; 2019; 13():1107-1115. PubMed ID: 31040647
[TBL] [Abstract][Full Text] [Related]
5. A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity.
Liu J; Qiu Z; Wang S; Zhou L; Zhang S
Biomed Mater; 2010 Dec; 5(6):065002. PubMed ID: 20924138
[TBL] [Abstract][Full Text] [Related]
6. Tf-PEG-PLL-PLGA nanoparticles enhanced chemosensitivity for hypoxia-responsive tumor cells.
Liu P; Zhang H; Wu X; Guo L; Wang F; Xia G; Chen B; Yin H; Wang Y; Li X
Onco Targets Ther; 2016; 9():5049-59. PubMed ID: 27574446
[TBL] [Abstract][Full Text] [Related]
7. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin.
Cui YN; Xu QX; Davoodi P; Wang DP; Wang CH
Acta Pharmacol Sin; 2017 Jun; 38(6):943-953. PubMed ID: 28552909
[TBL] [Abstract][Full Text] [Related]
8. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
9. The comparative study of influence of lactic and glycolic acids copolymers type on properties of daunorubicin loaded nanoparticles and drug release.
Nikolskaya E; Sokol M; Faustova M; Zhunina O; Mollaev M; Yabbarov N; Tereshchenko O; Popov R; Severin E
Acta Bioeng Biomech; 2018; 20(1):65-77. PubMed ID: 29658530
[TBL] [Abstract][Full Text] [Related]
10. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery.
Liu P; Yu H; Sun Y; Zhu M; Duan Y
Biomaterials; 2012 Jun; 33(17):4403-12. PubMed ID: 22436800
[TBL] [Abstract][Full Text] [Related]
11. Biocompatibility Assessment of Polyethylene Glycol-Poly L-Lysine-Poly Lactic-Co-Glycolic Acid Nanoparticles In Vitro and In Vivo.
Guo L; Chen B; Liu R; Xia G; Wang Y; Li X; Wei C; Wang X; Jiang H
J Nanosci Nanotechnol; 2015 May; 15(5):3710-9. PubMed ID: 26504996
[TBL] [Abstract][Full Text] [Related]
12. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.
Li Z; Huang H; Huang L; Du L; Sun Y; Duan Y
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28406431
[TBL] [Abstract][Full Text] [Related]
14. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
15. Impact of PEG and PEG-b-PAGE modified PLGA on nanoparticle formation, protein loading and release.
Rietscher R; Czaplewska JA; Majdanski TC; Gottschaldt M; Schubert US; Schneider M; Lehr CM
Int J Pharm; 2016 Mar; 500(1-2):187-95. PubMed ID: 26784983
[TBL] [Abstract][Full Text] [Related]
16. Influence of formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA.
Capan Y; Woo BH; Gebrekidan S; Ahmed S; DeLuca PP
J Control Release; 1999 Aug; 60(2-3):279-86. PubMed ID: 10425333
[TBL] [Abstract][Full Text] [Related]
17. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles.
Kuo YC; Lin PI; Wang CC
Nanomedicine (Lond); 2011 Aug; 6(6):1011-26. PubMed ID: 21707298
[TBL] [Abstract][Full Text] [Related]
18. [Preparation and in vitro evaluation of tetrandrine-loaded composite microspheres embedded with PLGA nanoparticles].
Shi C; Meng R; Li K
Zhongguo Zhong Yao Za Zhi; 2016 Mar; 41(5):838-844. PubMed ID: 28875636
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
20. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.
Aravind A; Jeyamohan P; Nair R; Veeranarayanan S; Nagaoka Y; Yoshida Y; Maekawa T; Kumar DS
Biotechnol Bioeng; 2012 Nov; 109(11):2920-31. PubMed ID: 22615073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
